EMA Authorised: Braftovi (Encorafenib) — Pierre Fabre Medicament

View source ↗

Summary

The EMA authorised Braftovi (encorafenib) for melanoma and colorectal cancer. Pierre Fabre Medicament is the marketing authorization holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Melanoma

Drugs mentioned

• BRAFTOVI (ENCORAFENIB)

Snippet

Status: Authorised. Therapeutic area: Melanoma;Colorectal Neoplasms. MAH: Pierre Fabre Medicament. Decision date: 18/09/2025